Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nastech Pharmaceutical Company has assigned certain of its licenses to third-party intellectual property and its own intellectual property, as such intellectual property relates to the development of RNA-based therapeutics, to its subsidiary MDRNA.
Subscribe to our email newsletter
Nastech’s intellectual property estate includes rights to issued and pending patent applications relating to RNA-based therapeutics which have broad claims on their development, delivery and use in treating diseases.
Steven Quay, chairman, president and CEO of Nastech, said: “The transfer of intellectual property rights for RNA-based therapeutics from Nastech to MDRNA is an important step in the process of creating MDRNA as an independent company. We believe MDRNA independence will ultimately enhance Nastech shareholder value. The MDRNA intellectual property estate includes rights to patents and patent applications covering technologies for the development and delivery of RNA-based therapeutics as well as their use in treating diseases. We believe that this agreement provides a strong foundation for MDRNA and will be important in attracting external funding for MDRNA.”